Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus
Authors
Discussion
Loading...
Member takes
Implication
Randomized trial shows fenofibrate plus simvastatin does not lower major cardiovascular events in type 2 diabetes, indicating routine combination lipid therapy offers no extra benefit.
Key Points
- To assess whether combining fenofibrate with simvastatin reduces the rate of major fatal and nonfatal cardiovascular events in high-risk patients with type 2 diabetes mellitus compared to simvastatin alone.
- Randomized clinical trial (ClinicalTrials.gov number, NCT00000620) conducted in high-risk patients with type 2 diabetes mellitus.
- Evaluated combination therapy using fenofibrate plus simvastatin versus simvastatin monotherapy.
- Combination therapy of fenofibrate and simvastatin did not reduce the rate of fatal cardiovascular events, nonfatal myocardial infarction, or nonfatal stroke compared with simvastatin alone (quantitative risk metrics not reported in abstract).
- Findings do not support the routine clinical use of fenofibrate plus simvastatin combination therapy for cardiovascular risk reduction in the majority of high-risk patients with type 2 diabetes.
Cite This Study
Henry N. Ginsberg (2010) studied this question.